学术探索
学术期刊
新闻热点
数据分析
智能评审

Erlotinib in gliomas: Should selection be based on EGFR and Akt analyses?

被引：17
作者：
Cappuzzo, F [1 ]
机构：
[1] Univ Bologna, Bellaria Hosp, Div Med Oncol, I-40139 Bologna, Italy
来源：
JOURNAL OF THE NATIONAL CANCER INSTITUTE | 2005年 / 97卷 / 12期
关键词：
D O I：
10.1093/jnci/dji169
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：868 / 869
页数：2
相关论文
共 22 条
  • [1] EXPRESSION OF THE EPIDERMAL GROWTH-FACTOR RECEPTOR IN ASTROCYTIC TUMORS IS SPECIFICALLY ASSOCIATED WITH GLIOBLASTOMA-MULTIFORME
    AGOSTI, RM
    LEUTHOLD, M
    GULLICK, WJ
    YASARGIL, MG
    WIESTLER, OD
    [J]. VIRCHOWS ARCHIV A-PATHOLOGICAL ANATOMY AND HISTOPATHOLOGY, 1992, 420 (04) : 321 - 325
  • [2] Somatic mutations of EGFR in colorectal cancers and glioblastomas
    Barber, TD
    Vogelstein, B
    Kinzler, KW
    Velculescu, VE
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2004, 351 (27) : 2883 - 2883
  • [3] BIGNER SH, 1990, CANCER RES, V50, P8017
  • [4] Epidermal growth factor receptor targeted therapy by ZD 1839 (Iressa) in patients with brain metastases from non-small cell lung cancer (NSCLC)
    Cappuzzo, F
    Ardizzoni, A
    Soto-Parra, H
    Gridelli, C
    Maione, P
    Tiseo, M
    Calandri, C
    Bartolini, S
    Santoro, A
    Crinò, L
    [J]. LUNG CANCER, 2003, 41 (02) : 227 - 231
  • [5] Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer
    Cappuzzo, F
    Hirsch, FR
    Rossi, E
    Bartolini, S
    Ceresoli, GL
    Bemis, L
    Haney, J
    Witta, S
    Danenberg, K
    Domenichini, I
    Ludovini, V
    Magrini, E
    Gregorc, V
    Doglioni, C
    Sidoni, A
    Tonato, M
    Franklin, WA
    Crino, L
    Bunn, PA
    Varella-Garcia, M
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2005, 97 (09): : 643 - 655
  • [6] Akt phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancer
    Cappuzzo, F
    Magrini, E
    Ceresoli, GL
    Bartolini, S
    Rossi, E
    Ludovini, V
    Gregorc, V
    Ligorio, C
    Cancellieri, A
    Damiani, S
    Spreafico, A
    Paties, CT
    Lombardo, L
    Calandri, C
    Bellezza, G
    Tonato, M
    Crinò, L
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2004, 96 (15): : 1133 - 1141
  • [7] Gefitinib in patients with brain metastases from non-small-cell lung cancer:: a prospective trial
    Ceresoli, GL
    Cappuzzo, F
    Gregorc, V
    Bartolini, S
    Crinó, L
    Villa, E
    [J]. ANNALS OF ONCOLOGY, 2004, 15 (07) : 1042 - 1047
  • [8] Chakravarti A, 2002, CANCER RES, V62, P200
  • [9] Enhanced sensitivity to the HER1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib hydrochloride in chemotherapy-resistant tumor cell lines
    Dai, Q
    Ling, YH
    Lia, M
    Zou, YY
    Kroog, G
    Iwata, KK
    Perez-Soler, R
    [J]. CLINICAL CANCER RESEARCH, 2005, 11 (04) : 1572 - 1578
  • [10] Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer
    Fukuoka, M
    Yano, S
    Giaccone, G
    Tamura, T
    Nakagawa, K
    Douillard, JY
    Nishiwaki, Y
    Vansteenkiste, J
    Kudoh, S
    Rischin, D
    Eek, R
    Horai, T
    Noda, K
    Takata, I
    Smit, E
    Averbuch, S
    Macleod, A
    Feyereislova, A
    Dong, RP
    Baselga, J
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (12) : 2237 - 2246
123